Ranibizumab
WR42221
Phase 3 small_molecule active
Quick answer
Ranibizumab for Neovascular Age-related Macular Degeneration (nAMD) is a Phase 3 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hoffmann-La Roche
- Indication
- Neovascular Age-related Macular Degeneration (nAMD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active